ARCT-2138 / Arcturus Therap - LARVOL DELTA

Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults (clinicaltrials.gov) - P1 | N=135 | Active, not recruiting | Sponsor: Arcturus Therapeutics, Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Oct 2024 ➔ Jan 2025

Enrollment closed • Trial completion date • Infectious Disease • Influenza • Respiratory Diseases